SCHEMBL6900816

SCHEMBL6900816

Nc1ncnc2c1ncn2[C@H]1O[C@H](CNCc2ccccc2)[C@H](O)[C@H]1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.76
DOT1L Q8TEK3 5/20 0.69
CARM1 Q86X55 3/20 0.68
AHCY P23526 2/20 0.67
ADORA3 P0DMS8 3/20 0.65
SLC29A1 Q99808 2/20 0.65
DPP4 P27487 1/20 0.65
MEN1 O00255 1/20 0.65
SLC28A1 O00337 1/20 0.65
MAP3K7 O43318 1/20 0.65
SLC28A2 O43868 1/20 0.65
GAPDH P04406 1/20 0.65
MAPK1 P28482 1/20 0.65
ADORA2A P29274 1/20 0.65
ADORA2B P29275 1/20 0.65
ADORA1 P30542 1/20 0.65
STAT6 P42226 1/20 0.65
PI4KA P42356 1/20 0.65
KMT2A Q03164 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26668606 0.89 GNMT (0.72) ATMDOT1LCARM1ADORA3SLC29A1
SCHEMBL11704731 0.88 CARM1 (0.77) ATMDOT1LCARM1AHCYADORA3
SCHEMBL20096928 0.87 ATM (0.67) ATMDOT1LCARM1AHCYADORA3
SCHEMBL25047833 0.87 DOT1L (0.73) ATMDOT1LCARM1AHCY
SCHEMBL31618018 0.87 DOT1L (0.73) ATMDOT1LCARM1AHCY
SCHEMBL19983463 0.86 CARM1 (0.73) ATMDOT1LCARM1AHCYADORA3
SCHEMBL19983432 0.86 CARM1 (0.73) ATMDOT1LCARM1AHCYADORA3
SCHEMBL6901588 0.86 DOT1L (0.67) DOT1LCARM1AHCYADORA3SLC29A1
SCHEMBL19111312 0.85 AMD1 (0.67) ATMDOT1LCARM1AHCYKMT2A
SCHEMBL16486809 0.85 ADORA1 (0.69) DOT1LAHCYADORA3SLC29A1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP ATM 1147/4885DOT1L 1250/4885CARM1 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.